Replimune Group (NASDAQ:REPL) Price Target Raised to $21.00

Replimune Group (NASDAQ:REPL) had its price objective upped by JPMorgan Chase & Co. from $20.00 to $21.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities research analysts have also recently commented on REPL. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research report on Tuesday, June 30th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Wednesday, August 12th. Finally, Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $15.50 on Wednesday. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -4.92 and a beta of 0.88. Replimune Group has a 1 year low of $1.50 and a 1 year high of $16.15. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The business has a fifty day simple moving average of $11.84 and a 200 day simple moving average of $8.34.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, sell-side analysts predict that Replimune Group will post -2.94 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other news, CEO Sushil Patel sold 39,341 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the transaction, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 91,124 shares of company stock worth $1,149,244 in the last 90 days. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC bought a new stake in shares of Replimune Group during the 4th quarter worth $29,000. CWM LLC grew its stake in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after buying an additional 2,886 shares during the last quarter. Allworth Financial LP bought a new position in Replimune Group in the 2nd quarter worth $62,000. Essential Partners LLC raised its holdings in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.